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Aims: To evaluate the accuracy of single-voxel Magnetic Resonance 
Spectroscopy (1H-MRS) as a non-invasive diagnostic aid for pediatric brain 
tumours in a multi-national study. Our hypotheses are (1) that automated 
classification based on 1H-MRS provides an accurate non-invasive diagnosis 
in multi-centre datasets and (2) using a protocol which increases the 
metabolite information improves the diagnostic accuracy.  
Methods: 78 patients under 16 years old with histologically proven brain 
tumours from 10 international centres were investigated. Discrimination of 29 
medulloblastomas, 11 ependymomas and 38 pilocytic astrocytomas was 
evaluated. Single-voxel MRS was undertaken prior to diagnosis (1.5Tesla 
PRESS, PROBE or STEAM, TE 20-32 ms, and 135-136 ms). MRS data was 
processed using two strategies, determination of metabolite concentrations 
using TARQUIN software and automatic feature extraction with Peak 
Integration. Linear Discriminant Analysis was applied to this data to produce 
diagnostic classifiers. An evaluation of the diagnostic accuracy was performed 
based on resampling to measure the Balanced Accuracy Rate (BAR). 
Results: The accuracy of the diagnostic classifiers for discriminating the three 
tumour types was found to be high (BAR 0.98) when a combination of TE was 
used. The combination of both TE significantly improved the classification 
performance (p < 0.01, Tukeyʼs test) compared with the use of one TE alone. 
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Other tumour types were classified accurately as glial or primitive 
neuroectodermal (BAR 1.00).  
Conclusions: 1H-MRS has excellent accuracy for the non-invasive diagnosis 
of common childhood brain tumours particularly if the metabolite information is 
maximised and should become part of routine clinical assessment for these 
children. 
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1  Introduction 
Brain tumours are the most prevalent form of solid cancer in children and the 
most common cause of death from cancer in childhood. Magnetic Resonance 
Imaging (MRI) is a key investigation in the initial diagnostic work-up of these 
patients, confirming the presence of a mass, its relationship to surrounding 
structures and the existence of metastatic disease. Sometimes, a diagnosis is 
made from clinical information combined with the MRI scan findings such as 
in children with Neurofibromatosis Type I and an optic pathway glioma. 
However, the conventional MR images are inaccurate in discriminating 
between most childhood brain tumours and a diagnosis is usually made from 
biopsy samples taken at operation with the histology of the tumour being used 
to formulate the treatment plan. Whilst histopathology provides a definitive 
diagnosis there would be several advantages to obtaining an accurate non-
invasive diagnosis. 
For tumours where surgical resection is not the initial therapeutic option, an 
accurate non-invasive diagnosis would avoid an invasive procedure. For 
tumours where surgery is undertaken at diagnosis, accurate diagnostic 
information on the tumour type prior to initial surgery would help surgical 
decision-making, allow timely adjuvant therapy planning and aid discussions 
with the family. A common site for childhood tumours is the cerebellum and 
surgical resection is usually the initial therapeutic intervention. However, the 
importance of a complete resection varies between the tumour types. A 
complete macroscopic resection is highly prognostic for ependymomas [1, 2], 
whereas small amounts of residual medulloblastoma (up to 1.5cm2) are not of 
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prognostic significance if treated with radiotherapy and chemotherapy [3] and 
small residual masses of pilocytic astrocytoma may be observed without 
further treatment [4]. Histopathology is usually not available for several days 
after the operation and intraoperative histopathology is commonly used to 
inform the surgeons of the likely tumour type but the techniques available are 
not accurate [5] and this strategy does not allow patient-specific clinical 
management planning prior to surgery. With improved adjuvant treatment, 
therapeutic strategies may evolve to ones in which surgery is undertaken at a 
later point, which is already common for childhood tumours outside the brain. 
Histopathology remains the ʻgold standardʼ for classifying childhood brain 
tumours and is the basis for treatment planning in the majority of cases. 
However, patients with identical histopathological diagnosis can respond in 
different ways to treatment and there is increasing evidence that additional 
information from tumour biology can improve the classification [6]. Advances 
in imaging have allowed tissue properties to be probed non-invasively giving 
important insights into in vivo tumour biology [7]. The aims of modern imaging 
are therefore not just to give a non-invasive histological diagnosis but rather to 
improve the classification of tumours. 
Multivariate analysis of automated MRS processing is a powerful technique 
that can yield rapid and robust results and promises to translate into routine 
clinical practice. However, a multi-centre evaluation of these techniques is 
required. Although a large number of multi-centre studies on automatic 
classification of brain tumours has been reported in adults [8-15], these 
results cannot be extrapolated to children since the overall distribution of the 
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tumour types, locations and etiology differs markedly from that of adults [16-
19]. Establishing the optimal MRS acquisition protocol is important and MRS 
can potentially give accurate quantification of more metabolites by using a 
longer acquisition, which combines Short echo time (Short-TE) and Long echo 
time (Long-TE) MRS [20], but this has currently not been reported in pediatric 
brain tumours. The present study investigates the accuracy of tumour 
metabolite profiles measured by 1H-MRS as a diagnostic aid for common 
childhood brain tumours. The main aim of this work is, to evaluate the 
automatic classification of pediatric brain tumours in a large multi-centre 1H-
MRS study. In addition we test whether increasing the metabolite information 
available improves the automatic classification of pediatric brain tumours by 
comparing the combination of Short-TE and Long-TE MRS with the use of one 
echo time (TE) alone. 
2  Methods 
2.1 Data acquisition 
The study includes 97 patients under 16 years old (mean age 7.3±4.7) with 
histologically proven brain tumour collected from 10 international centres in 
the framework of the eTUMOUR project (2004-2009) [21]. Histopathological 
diagnoses were validated in the context of clinical setting and radiological 
images and reviewed by the multidisciplinary Clinical Validation Committee. 
MRS data was reviewed for quality control by expert spectroscopists of 
eTUMOUR [8, 22]. 
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The classes considered in this study were defined according to the WHO 
histological classification of the CNS tumours [23]. The cases were distributed 
as follows: 38 Pilocytic Astrocytoma (PILOA), 20 of them in the Posterior 
Fossa (PF); 11 Ependymoma grade II (EPEN), 7 in the PF; 29 
Medulloblastoma (MED), all in the PF; Additionally we included 10 Diffuse 
Astrocytoma (DASTRO), 3 in the PF; 3 Subependymal giant cell astrocytoma 
(SASTRO), 2 in the ventricular atrium and 1 in the frontal lobe; one 
Supratentorial PNET located in the frontal lobe; 3 Atypical Teratoid Rhabdoid 
Tumour (ATRT), 2 in the PF; and 2 Pineoblastoma (PINEOB) in the pineal 
region. Table 1 documents the available cases. 
Acquisition protocols for clinical, radiological and histopathological data were 
defined to ensure the compatibility of the data acquired [22, 24]. 
Single voxel 1H-MRS at 1.5T from 90 patients were acquired at Short-TE and 
61 spectra at Long-TE from Philips, Siemens and General Electric scanners. 
All patients had just one voxel placed and none were scanned on another 
occasion or scanner. Both TE were acquired in 54 patients with no change in 
voxel position or other parameters. Conventional MRI required for the clinical 
assessment of the child, including contrast enhanced imaging, was performed 
prior to the MRS acquisition. For each patient, the voxel was placed within the 
tumour to maximise the contrast enhancing region covered or, if non-
enhancing, the high T2 region, whilst avoiding necrosis and CSF identified on 
the structural images. Voxels were cubic, with a side length of 1.5cm or 
2.0cm, with 248 or 128 acquisitions respectively. Review of the voxel position 
was undertaken by the clinical validation committee. The acquisition protocols 
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for Short-TE included PRESS, PROBE or STEAM sequences, with Recycling 
Time (TR) of 1500-2000ms, TE of 20 or 30ms, spectral width of 500-2500Hz, 
and 512, 1024 or 2048 data-points. Long-TE spectra were acquired with 
PRESS sequence with TR of 1500-2020ms, TE of 135 or 136ms, spectral 
width of 1000-2500Hz and 512 or 2048 data-points. 
2.2 MRS processing 
Two MRS processing methods were compared: MRS quantitation of 
metabolite concentrations using the TARQUIN software (version 4.1.1) [25]; 
and the automatic feature extraction technique of Peak Integration (PI) [15, 
26]. 
MRS processing with TARQUIN was performed with the standard metabolite 
library provided [25]. 21 metabolite, lipid and macromolecule variables were 
quantified. Details are given in the Supplementary Material. 
The PI technique was also applied to estimate the relative concentration of 
metabolites. PI automatically estimates with proportionality to the 
concentration of 11 main metabolites for Short-TE and 8 metabolites for Long-
TE MRS [15, 26]. Details of these estimations are given in the Supplementary 
Material. PI was applied after a semiautomatic processing pipeline defined in 
[20]. 
12 cases failed the inclusion criteria for QC mainly due to poor SNR. 
2.3 Classification and evaluation 
 9 
The diagnostic classification problem of discriminating between EPEN, PILOA 
and MED, the three most common pediatric tumour types, is addressed in this 
study. Since EPEN and PILOA tumours can be found in brain locations other 
than the PF whereas MED are found only in the PF, training was undertaken 
twice, once using the tumour cases located in the PF and then with those in 
any brain location. Classifiers were designed and evaluated using features 
from Short-TE and Long-TE alone and a combination of both TEs, Short-
TE+Long-TE. Our results were compared with those in previous studies [27-
30]. 
Based on the results of previous studies [15, 20, 26, 29, 30], we chose Linear 
Discriminant Analysis (LDA) as the classification technique. Classifiers were 
evaluated with a k-Random Sampling Train-Test strategy and the 
performance measured with Balanced Accuracy Rate (BAR), which is the 
average of the success rate obtained for each tumour class [31]. Details about 
the evaluation methodology are described in the Supplementary Material. 
3  Results 
3.1 Spectral features 
Several key features allow visual discrimination of PILOA, EPEN and MED. 
Figures 1 and 2 show the Short-TE and Long-TE mean spectra of the tumour 
types. Minimum differences are found between the mean spectra of the 
tumours in the PF and those in any location. All tumour spectra display an 
increase in Cho peak (3.2ppm) with respect to Cr peak (3.0ppm). NAA 
(2.0ppm) presents a less prominent peak in MED and EPEN compared with 
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PILOA. Elevation of macromolecules and lipids (0.9ppm and 1.3ppm) is 
observed in Short-TE. Regarding Long-TE, the inverted peak of Lac at 
1.3ppm is distinguished in PILOA and EPEN but not in MED. 
3.2 Univariate metabolite comparison 
Tables 2 and 3 show the metabolite concentrations estimated with TARQUIN 
in Short-TE and Long-TE for the three tumour types found in any brain 
location. The Kruskal-Wallis test for the analysis of the variance (α=0.05) was 
applied to determine the significant differences in metabolite concentrations of 
PILOA, EPEN and MED. Both Cho components, Glycerophosphocholine 
(GPC) and Phosphocholine (PCh) (p≤0.01) showed significant differences. Cr 
and Tau concentrations were significantly different in both TEs (p≤0.01). 
Differences in the mI concentrations (p≤0.01) were significant in Short-TE.  
Macromolecules and lipids at 0.9, 1.3 and 2.0ppm (p≤0.05, p≤0.01 and 
p≤0.01, respectively) exhibited statistical differences in Short-TE MRS.  
3.3 Classification 
Table 4 summarizes the classification results in the discrimination of PILOA, 
EPEN and MED found in the PF and those in any brain location. The table 
shows the performance when using Short-TE, Long-TE and Short-TE+Long-
TE. Each discrimination was undertaken with the quantitation estimated with 
TARQUIN and PI. 
The discrimination of the three classes obtained a BAR of 0.79 for Short-TE, 
0.83 for Long-TE and 0.98 for Short-TE+Long-TE. The best performance was 
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obtained with Short-TE+Long-TE, showing a significant improvement (p<0.01, 
Tukeyʼs test, α=0.01) compared to the best performance obtained with either 
TE alone. The BAR of the classifiers trained with tumours from any location 
was slightly higher than that of the models trained only with the PF tumours. 
Comparable performances were obtained with TARQUIN and PI. 
Figure 3 shows the clustering of cases in LDA latent spaces from Short-TE, 
Long-TE and Short-TE+Long-TE obtained for the discrimination of PILOA, 
EPEN and MED located in the PF. In addition, Figure 3-d shows the 
corresponding result from Short-TE for the three tumour types in any brain 
location. 
Other tumour types were classified as glial or primitive neuroectodermal 
according to the result with the classifier developed for PILOA, EPEN and 
MED. A BAR of 0.91 was obtained with Short-TE, 0.67 for Long-TE and 1.00 
was achieved with Short-TE+Long-TE. Figure 4 shows how these other 
tumour types cluster when projected onto Figure 3-d and illustrates the 
potential for generalization of our classifiers to other tumour types: The ATRT 
and PNET cases fall close to the boundaries of the MED area, the only 
exception being the ATRT case located in the frontal lobe. The DASTRO and 
SASTRO cases are spread all over the PILOA and EPEN area, never within 
the MED area.  
4  Discussion 
This is the first study of MRS as a non-invasive diagnostic aid in childhood 
brain tumours to be performed across a large number of centres. Limited 
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single-centre studies have been reported including the non-invasive diagnosis 
and characterization of EPEN, MED and PILOA: Wang et al. [27] collected 
data from 26 patients using a Long-TE MRS technique. They obtained an 
accuracy of 0.85 discriminating the three tumour types using the metabolites 
ratios NAA:Cho and Cr:Cho. Arle et al. [28] obtained an accuracy of 0.88 with 
a neural network using metabolites ratios of NAA, Cho and Cr from MRS data 
of 33 patients. Schneider et al. [29] combined Short-TE MRS and diffusion-
weighted imaging data from 17 patients, obtaining an accuracy of 1.00 when 
applying an LDA with seven variables from the diffusion-weighted image and 
six metabolites. Davies et al. [30] used an automated method for fitting MRS 
data of 35 patients to quantify 25 metabolite, lipid and macromolecule 
concentrations and used this as an input to an LDA. They reported an 
accuracy of 0.93 when discriminating the three tumour types. In our study, the 
performances of classifiers using one TE were similar to those reported in 
these studies [27-30]. 
Significant differences in metabolite concentrations of PILOA, EPEN and MED 
were found. Cho was higher (p≤0.01) in MED (grade IV) and EPEN (grade II) 
compared to PILOA (grade I) in agreement with Cho as an indicator of cell 
proliferation and tumour malignancy [17, 18]. EPEN and MED have higher 
concentrations of lipids and macromolecules, associated with hypoxia, 
apoptosis and necrosis and linked to high malignancy and poor survival [33, 
34]. As previously reported [35, 36, 37], Tau concentration is significantly 
higher in MED than glial tumours (p≤0.01) and further investigation of the role 
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of this metabolite in these tumours is warranted. Low concentrations of Cr 
were seen in PILOA as in previous studies but remain unexplained [30].   
A significant improvement (p<0.01, Tukeyʼs test, α=0.01) in the diagnosis 
rates was obtained when the metabolite information was increased with the 
combination of both TEs compared to the performance when using either TE 
alone. This finding has been reported for adult cases in [20] but not for 
pediatric brain tumours. 
Estimation of metabolite concentrations was performed with the TARQUIN 
software (Tables 2 and 3) which is a highly automated and stable method for 
determining metabolite concentrations from MRS data and allows a non-
expert user to process MRS spectra at various echo times without difficulty. 
The use of TARQUIN quantitation in automatic Decision Support Systems 
(DSSs) provides a powerful clinical tool. The CURIAM DSS [37, 38] 
incorporates the classifiers developed in this work, offering the possibility of 
giving decision support both to the non-invasive diagnosis of brain tumours in 
adults and children. 
Future work should focus on optimising MRS in providing non-invasive 
biomarkers of prognosis and whether it adds prognostic information to that 
from histology and structural imaging. 
5  Conclusion 
1H-MRS data was collected at diagnosis from children with brain tumours in 
10 international centres in Europe and South America and was used to test 
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the ability of MRS to discriminate between different tumour types. Our results 
show that particularly high diagnostic accuracies are achieved when MRS is 
collected at two TEs and that this accuracy can be achieved with data 
collected from multiple centres. MRS with automated processing and pattern 
recognition provides a useful technique for accurate, non-invasive diagnosis 
and classification of childhood brain tumours and thereby a powerful 
diagnostic tool for clinical practice. 
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Acronyms 
Ala  Alanine 
Asp  Aspartate 
ATRT  Atypical Teratoid Rhabdoid Tumour 
BAR  Balanced Accuracy Rate 
Cho  Choline 
CNS  Central Nervous System 
Cr  Creatine 
DASTRO Diffuse Astrocytoma  
DSS  Decision Support System  
EPEN  Ependymoma grade II  
GABA  γ Aminobutyric acid 
Glc  Glucose  
Gln  Glutamine  
Glu  Glutamate 
Glx  Glutamate + Glutamine 
Gly  Glycine 
GPC  Glycerophosphocholine 
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Gua  Guanidinoacetate 
Lac  Lactate 
LDA  Linear Discriminant Analysis 
Long-TE Long echo time  
MED  Medulloblastoma  
mI  myo-Inositol 
MMLip09 Macromolecules and lipids components at 0.9 ppm  
MMLip13 Macromolecules and lipids components at 1.3 ppm  
MMLip20 Macromolecules and lipids components at 2.0 ppm  
MR  (Nuclear) Magnetic Resonance 
MRI  Magnetic Resonance Imaging 
MRS  Magnetic Resonance Spectroscopy 
NAA  N-Acetyl Aspartate 
PCh  Phosphocholine  
PI  Peak Integration  
PILOA Pilocytic Astrocytoma  
PINEOB Pineoblastoma 
PF  Posterior Fossa 
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PNET  Supratentorial PNET 
PRESS Point-Resolved Spectroscopy 
PROBE Proton Brain Exam 
ppm  parts per million 
SASTRO Subependymal giant cell astrocytoma 
Scyllo scyllo-inositol 
Short-TE Short echo time 
STEAM Stimulated Echo Acquisition Mode 
Tau  Taurine 
TE  Echo Time 
TR  Recycling Time 
WHO  World Health Organization 
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Figure 1 Short-TE mean spectra of tumours located in the PF (left) and in any other location than 
PF (right) with standard deviation by the shaded region. Number of patients is indicated beneath 
each graph. 
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Figure 2 Long-TE mean spectra of tumours located in the PF (left) and in any other location than 
PF (right) with standard deviation by the shaded region. Number of patients is indicated beneath 
each graph. 
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Figure 3 LDA latent space for the discrimination of PILOA, EPEN and MED located in the PF 
using PI applied to: a) Short-TE; b) Long-TE; and c) both echo times. Each triangle represents 
the centroid of each cloud of samples. Figure d) represents the LDA latent space for 
discrimination of PILOA, EPEN and MED using PI applied to Short-TE for tumours located in the 
PF (represented with `x') and other locations (represented with `o'). 
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Figure 4 LDA latent space for the discrimination of Medulloblastoma (MED), Pilocytic 
Astrocytoma (PILOA) and Ependymoma grade II (EPEN) using PI applied to Short-TE. The 
proyection of Subependymal giant cell astrocytoma (SASTRO), Diffuse Astrocytoma (DASTRO), 
Atypical Teratoid Rhabdoid Tumour (ATRT), Supratentorial PNET (PNET) and Pineoblastoma 




Table 1 Number of cases. 




PILOA 37 27 26 38 
EPEN 9 7 5 11 
MED 28 15 13 29 
SASTRO 2 3 2 3 
DASTRO 8 8 6 10 
ATRT 3 0 0 3 
PNET 1 1 1 1 
PINEOB 2 0 0 2 





Table 2 Estimated metabolite concentrations (mM) at several ppm calculated with TARQUIN 
relative to total water from Short-TE spectra. The standard error of the concentrations is given 
in brackets. The p-value of the analysis of the variance (Kruskal-Wallis test, α=0.05) is shown for 
discrimination of PILOA, EPEN and MED when significant differences are observed. 
  Short-TE   
  Tumour type  p-value 
Metabolite PILOA (mM) EPEN (mM) MED (mM) PILOA vs EPEN vs MED 
Ala 0.9 (0.9) 2.5 (2.3) 0.6 (0.5) - 
Cr 1.3 (1.1) 3.4 (1.5) 3.6 (1.9) <0.01 
Glc 2.7 (1.7) 2.3 (1.8) 1.9 (1.2) <0.01 
Gln 3.7 (1.9) 6.7 (3.0) 4.1 (3.1) - 
Glu 2.0 (1.6) 3.1 (3.2) 2.5 (1.5) - 
mIa 2.1 (1.9) 9.0 (5.3) 5.3 (3.2) <0.01 
Lac 2.4 (1.9) 3.2 (4.3) 2.9 (3.0) - 
NAA 1.6 (1.4) 1.1 (0.3) 1.5 (1.0) - 
Scyllo 0.7 (0.8) 0.6 (0.4) 0.9 (0.5) <0.05 
Tau 1.8 (1.3) 1.8 (1.6) 4.5 (3.6) <0.01 
GPC 0.9 (0.4) 1.6 (0.5) 2.2 (1.2) <0.01 
PCh 1.6 (2.4) 1.3 (1.0) 2.2 (1.6) <0.01 
-CrCH2 1.7 (1.8) 3.2 (1.9) 1.3 (1.1) - 
Gua 1.8 (1.7) 1.2 (1.2) 2.1 (2.0) - 
GABA 3.8 (7.9) 2.2 (1.7) 2.9 (3.5) - 
Asp 9.1 (24.2) 4.5 (3.6) 3.6 (2.7) - 
Cho: GPC+PCh 1.4 (1.6) 2.4 (1.1) 4.1 (1.4) <0.01 
Glx: Glu+Gln 4.9 (2.2) 8.9 (4.2) 5.5 (3.1) <0.05 
MMLip09 4.9 (2.9) 8.1 (5.5) 8.3 (5.9) <0.05 
MMLip13 7.7 (7.0) 27.3 (17.6) 20.5 (18.9) <0.01 
MMLip20 6.2 (2.9) 10.8 (3.3) 11.3 (5.2) <0.01 
a Concentration of mI may contain Gly contribution. Gly was not included in the TARQUIN basis-set.  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Table 3 Estimated metabolite concentrations (mM) at several ppm calculated with TARQUIN 
relative to total water from Long-TE spectra. The standard error of the concentrations is given in 
brackets. The p-value of the analysis of the variance (Kruskal-Wallis test, α=0.05) is shown for 
discrimination of PILOA, EPEN and MED when significant differences are observed. 
  Long-TE   
  Tumour type  p-value 
Metabolite PILOA (mM) EPEN (mM) MED (mM) PILOA vs EPEN vs MED 
Ala 0.5 (0.5) 0.9 (1.1) 1.4 (0.8) <0.05 
Cr 1.8 (1.9) 5.8 (2.2) 5.6 (2.1) <0.01 
Glc 2.1 (1.9) 7.2 (5.4) 3.0 (1.8) - 
Gln 3.3 (2.1) 7.2 (3.5) 3.4 (2.1) - 
Glu 2.8 (2.8) 5.3 (1.9) 5.8 (2.3) - 
mIb 7.5 (10.4) 24.1 (14.8) 31.1 (14.5) <0.01 
Lac 2.0 (1.5) 2.2 (1.0) 1.9 (1.7) - 
NAA 1.9 (1.2) 2.4 (1.3) 2.3 (1.6) - 
Scyllo 0.3 (0.3) 0.9 (0.6) 0.8 (0.6) - 
Tau 1.6 (2.6) 4.3 (4.5) 6.9 (6.4) <0.01 
GPC 0.8 (1.1) 2.1 (1.3) 4.1 (4.2) <0.01 
PCh 1.9 (2.0) 3.0 (0.9) 5.7 (5.6) <0.01 
-CrCH2 0.7 (0.8) 3.9 (3.2) 3.4 (3.1) - 
Gua 0.7 (0.5) 1.5 (0.1) 0.7 (0.4) - 
GABA 1.5 (1.1) - 1.3 (0.8) - 
Asp 1.5 (0.6) 2.4 (1.3) 3.4 (3.1) - 
Cho: GPC+PCh 2.4 (2.7) 4.3 (1.9) 9.5 (5.9) <0.01 
Glx: Glu+Gln 5.7 (3.1) 10.5 (4.9) 7.4 (3.5) - 
MMLip09 0.4 (0.3) 1.8 (1.1) 0.5 (0.2) <0.05 
MMLip13 1.3 (1.3) 9.2 (8.8) 3.6 (2.0) <0.05 
MMLip20 2.0 (2.5) 1.6 (1.3) 1.2 (0.9) - 




Table 4 Balanced Accuracy Rate (BAR) of the classifiers trained with Short-TE, Long-TE and 
combination of both echo times (Short-TE+Long-TE) for discrimination of PILOA, EPEN and 
MED. 
PILOA vs EPEN vs MED 
 Cases from tumours located in the PF Cases from any brain tumour location 
 Short-TE Long-TE Short-TE+Long-TE Short-TE Long-TE Short-TE+Long-TE 
TARQUIN 0.67 0.94 0.96 0.79 0.83 0.98 
PI 0.65 0.62 0.90 0.76 0.69 0.92 
 
 
 
